The economics of improved cancer survival rates: Better outcomes, higher costs

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 3, 2010, Pages 283-292

  Uyl De Groot, Carin A ^a   De Groot, Saskia ^a   Steenhoek, Adri ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

burden; cancer; costs; incidence; mortality; survival

Indexed keywords

ADALIMUMAB; ANASTROZOLE; ATORVASTATIN; BEVACIZUMAB; BICALUTAMIDE; BORTEZOMIB; CAPECITABINE; CETUXIMAB; DOCETAXEL; FLUOROURACIL; FLUTICASONE PROPIONATE PLUS SALMETEROL; GEMCITABINE; GOSERELIN; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; IRINOTECAN; LENALIDOMIDE; LEUPRORELIN; OXALIPLATIN; PANITUMUMAB; PEMETREXED; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TAXOID; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

AGING; B CELL LEUKEMIA; B CELL LYMPHOMA; BLADDER CANCER; BLEEDING; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; DRUG ERUPTION; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; KIDNEY CANCER; LUNG CANCER; NEUROPATHY; NONHODGKIN LYMPHOMA; POPULATION GROWTH; PREVALENCE; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; ECONOMICS; EPIDEMIOLOGY; EUROPE; GENETIC SCREENING; HEALTH CARE DELIVERY; MASS SCREENING; METABOLISM; NEOPLASMS; PATIENT SELECTION; PROCEDURES;

ANTINEOPLASTIC AGENTS; EUROPE; GENETIC TESTING; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MASS SCREENING; NEOPLASMS; PATIENT SELECTION; QUALITY OF HEALTH CARE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953701801     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.27     Document Type: Review

References (28)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007).
2. Albreht TM, McKee M, Alexe DM, Coleman MP, Martin-Moreno JM. Making progress against cancer in Europe in 2008. Eur. J. Cancer 44, 1451-1456 (2008).
3. Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. J. Clin. Oncol. 25(2), 169-170 (2007).
4. Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur. J. Cancer 44, 1404-1413 (2008).
5. Fass L. Imaging and cancer: a review. Mol. Oncol. 2, 115-152 (2008).
6. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101(15), 1044-1048 (2009).
7. Otto SJ, Fracheboud J, Looman CWN et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361, 1411-1417 (2003).
8. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
9. Wong Y. Financial consequences of improved treatments for colorectal cancer. Semin. Colon Rectal Surg. 19(4), 247-252 (2008).
10. Karim-Kos HE, Janssen-Heijnen MLG, van Iersel CA, van der Meer RM, de Vries E, Coebergh JWW. Longkanker bij Nederlandse vrouwen: het einde in zicht. Nederlands Tijdschrift voor Geneeskunde 152, 1473-1477 (2008).
11. Wheatley-Price P, Blackhall F, Thatcher N. The influence of sex in non-small cell lung cancer. Onkologie 32, 547-548 (2009).
12. Bosanquet N, Sikora K. The economics of cancer care in the UK. Lancet Oncol. 5, 568-574 (2004).
13. Ramsey S. What do we want from our investment in cancer research? A departure from the focus on how much money Americans spend to defeat cancer. Health Affairs W5(R), 101-104 (2005).
14. Civan A, Köksal B. The effect of newer drugs on health spending: do they really increase the costs? Health Econ. 19(5), 581-595 (2009).
15. Heijink R, Noethen M, Renaud T, Koopmanschap MA, Polder JJ. Cost of illness: an international comparison Australia, Canada, France, Germany and The Netherlands. Health Policy 88, 49-61 (2008).
16. Polder JJ, Meerding WJ, Koopmanschap MA, Bonneux L, van der Maas PJ. Kosten van Ziekten in Nederland 1994. Instituut Maatschappelijke gezondheidszorg, Rotterdam, The Netherlands (1997).
17. Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Kosten van Ziekten in Nederland, de Zorgeuro Ontrafeld (Report no. 270751005). Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, The Netherlands 5, R (2002).
18. Stichting Farmaceutische Kengetallen. Monitor dure geneesmiddelen 2008, kosten van dure- en weesgeneesmiddelen in het ziekenhuis. (2010) (In press).
19. Uyl-de Groot CA, McDonnell J, Groen HJM, Radice D, Velde GT. Cost-effectiveness of new drugs in patients with Phase IIIB-IV non-small cell lung cancer: results of a Markov chain model. Eur. J. Hosp. Pharmacy Sci. 11(2), 37-41 (2005).
20. Uyl-de Groot CA, Stupp R, van der Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev. Pharmacoeconomics Outcomes Res. 9(3), 235-241 (2009).
21. Boyle P, Levin B. World cancer report (2008) www.iarc.fr/en/publications/ pdfs-online/ wcr/
22. Wilking N, Jönsson B, Högberg D. Comparator report on patient access to cancer drugs in europe (2009) www.comparatorreports.se/
23. OECD Health Data www.ecosante.org/
24. Dutch cancer registry www.ikcnet.nl/
25. OECD Health Care Quality Indicators Data 2009 www.oecd.org/
26. Poos MJJC, Smit JM, Groen J, Kommer GJ, Slobbe LCJ. Cost of illness in The Netherlands 2005 (RIVM 2008) www.costofillness.nl/
27. GIP/ College voor zorgverzekeringen (2009) www.gipdatabank.nl/
28. Foundation for Pharmaceutical Statistics www.sfk.nl